Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Search results for

There are 12,819 results that match your search.12,819 results
  • Prietika Siingh and Dheeraj Seth of Inttl Advocare discuss the registrability of well-known trade marks
  • Welcome to Managing IP's seventh India IP Focus. Not only is this year's edition by far the largest ever, with 20 articles, it is also the first to be published as a separate supplement. This move shows the increasing importance of intellectual property to companies doing business in India and also the increasing range of topics that IP owners need to be familiar with.
  • Anuradha Salhotra of Lall Lahiri & Salhotra discusses copyright and domain name issues for IT, software and internet businesses
  • Mita Sheikh of Krishna & Saurastri Associates discusses Myriad and the Indian position on gene patents
  • Australia has just had its second federal court decision involving our rather controversial second tier patent system, the innovation patent. In the case, Seafood Innovations Pty Ltd v Richard Bass Pty Ltd [2010] FCA 723 (July 12 2010), the plaintiff sued over two innovation patents in the field of fish processing machinery. It is noteworthy that the second of the innovation patents was granted after the litigation had commenced and the plaintiff had seen a detailed response from the defendant on non-infringement.
  • In a controversial resolution, the Argentine IP office, INPI, has established limitations on the filing of divisional patent applications, arguing that divisional applications increase the number of applications to be examined, therefore increasing the backlog of pending applications to be resolved.
  • Manisha Singh Nair of LEXORBIS IP Practice discusses recent court decisions in relation to pharmaceutical patents
  • Peter Ollier, Hong Kong and Simon Crompton, London
  • The doctrine of exhaustion or the first sale rule affirms the exhaustion of an asset's intellectual property rights vested with its owner after its first use or sale. As a result, no further control can be exercised by the owner vis-à-vis distribution or resale of the product. Applying the principle more specifically to the realm of copyrights, it allows the purchaser to sell or give away a legally made copy of a copyrighted work without permission once it has been obtained. The copyright holder's right to control any further change in ownership of a particular copy ends once that copy is sold, as long as no additional copies are made. Thus, the rule of exhaustion has the power to interfere with the copyright owner's exclusive market position, reducing any leeway for price differentiation and exposing the product to intensified price competition.
  • Where is the line between patent-protectable new medical indications and ineffective dietary supplements (the latter not being eligible for use-restricted product protection under the EPC)?